%PDF-1.7
%
1 0 obj
<>>>
endobj
2 0 obj
<>stream
2016-10-12T08:06:55-04:00
2016-10-12T08:07:12-04:00
2016-10-12T08:07:12-04:00
Adobe InDesign CC 2015 (Windows)
uuid:5731d3dc-e9b4-4388-9870-8e63cbc04db5
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
xmp.id:c2ff3ad2-6b71-f04b-8ff6-7f607bb08215
proof:pdf
xmp.iid:df0acb60-dfb7-af46-bce8-2c4f0ffa13cc
xmp.did:dcf8b759-e1aa-274a-a065-1159b7e3d27a
xmp.did:4A42F9656056E111960DCE8E95F0DF9D
default
converted
from application/x-indesign to application/pdf
Adobe InDesign CC 2015 (Windows)
/
2016-10-12T08:06:55-04:00
application/pdf
Adobe PDF Library 15.0
False
endstream
endobj
3 0 obj
<>
endobj
5 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
6 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/Properties<>/XObject<>>>/TrimBox[0.0 0.0 612.0 792.0]/Type/Page>>
endobj
17 0 obj
<>stream
BT
0 0 0 1 k
/GS0 gs
/TT0 1 Tf
7 0 0 7 60.48 22.6817 Tm
(2 )Tj
/Span<>> BDC
( )Tj
EMC
59.297 0 Td
[(Pharmacology W)54.6 (atch)]TJ
4.081 0 0 4.081 535.1605 25.0127 Tm
(\256)Tj
ET
q
0 g
/GS1 gs
0 TL/Fm0 Do
Q
BT
/T1_0 1 Tf
-0.01 Tc 7 0 0 7 40.75 257.75 Tm
(PHARMACOLOGY WATCH)Tj
/T1_1 1 Tf
6 0 0 6 127.892 257.75 Tm
[(\231 is published monthly by AHC Media, LLC. Copyright \251)-10 ( )]TJ
-14.524 -1.167 Td
[(2016 AHC Media, LLC.)-10 ( )]TJ
/T1_2 1 Tf
0.01 Tw 8 0 0 8 40.75 240.75 Tm
(Author)Tj
/T1_1 1 Tf
(: )Tj
/T1_3 1 Tf
0 Tw 3.698 0 Td
(William T. Elliott, MD, FACP, )Tj
/T1_1 1 Tf
[(Medical Director, Pharmacy,)-9.9 ( )]TJ
-3.698 -1.25 Td
[(Northern California Kaiser Permanente Assistant Clinical Professor of)-9.9 ( )]TJ
0 -1.25 TD
(Medicine, University of California, San Francisco)Tj
/T1_2 1 Tf
T*
(Executive Editor:)Tj
/T1_1 1 Tf
( Leslie Coplin)Tj
/T1_2 1 Tf
T*
(Assistant Editor:)Tj
/T1_1 1 Tf
( Jonathan Springston)Tj
6 0 0 6 40.75 189.25 Tm
[(This is an educational publication designed to present scientific inform\
ation and opinion to)-10 ( )]TJ
0 -1.167 TD
[(health professionals, stimulate thought, and further investigation. It d\
oes not provide advice)-10 ( )]TJ
0 -1.167 TD
[(regarding medical diagnosis or treatment for any individual case. It is \
not intended for the)-10 ( )]TJ
0.01 Tw 0 -1.167 TD
(layman.)Tj
0.01 Tc 0 Tw 0 -1.917 TD
(STATEMENT OF FINANCIAL DISCLOSURE)Tj
-0.01 Tc 0 -1.167 TD
[(To reveal any potential bias in this publication, and in accordance with\
Accreditation Council)-9.9 ( )]TJ
0 -1.167 TD
[(for Continuing Medical Education guidelines, Dr. Elliott, Ms. Coplin, an\
d Mr. Springston)-10 ( )]TJ
T*
(report no financial relationships relevant to this field of study.)Tj
ET
/CS0 CS 1 SCN
0.25 w 4 M
/GS1 gs
36.125 45.125 251.75 222.5 re
S
/CS0 cs 0.1 scn
122.4 50.76 160.85 69.12 re
f
0.86 0.57 0 0.16 K
0.3 w 10 M
q 1 0 0 1 151.4756 83.3042 cm
0 0 m
42.017 0 l
S
Q
BT
0 0 0 1 k
/GS0 gs
/T1_2 1 Tf
0.05 Tc 8 0 0 8 126.9 108.1801 Tm
[(SUBSCRIBER INFORMA)92 (TION)]TJ
-0.01 Tc 7 0 0 7 126.9 97.9041 Tm
(Customer Service: \(800\) 688-2421)Tj
/T1_1 1 Tf
6 0 0 6 126.9 90.9041 Tm
(Email Address: Jonathan.Springston@AHCMedia.com)Tj
0.01 Tw T*
(Website: )Tj
0.86 0.57 0 0.16 k
/GS1 gs
4.096 0 Td
(AHCMedia.com)Tj
0 0 0 1 k
/GS0 gs
0 Tw -4.096 -1.917 Td
[(Address Correspondence to: AHC Media, One Atlanta)-10 ( )]TJ
T*
[(Plaza, 950 East Paces Ferry Road NE, Suite 2850, Atlanta,)-9.9 ( )]TJ
T*
[(GA 30326.)-10 ( )]TJ
ET
/PlacedGraphic /MC0 BDC
EMC
q
44.685 73.418 70.72 32.443 re
W n
/GS1 gs
q 1 0 0 1 52.0285 92.6745 cm
0 0 m
-0.027 0 l
-0.163 -0.531 -0.313 -1.171 -0.463 -1.715 c
-1.171 -3.975 l
1.184 -3.975 l
0.463 -1.715 l
0.286 -1.157 0.136 -0.531 0 0 c
f
Q
q 1 0 0 1 70.4899 86.0851 cm
0 0 m
0.667 0 1.375 0.136 1.824 0.327 c
2.097 -0.994 l
1.702 -1.184 0.831 -1.402 -0.286 -1.402 c
-3.199 -1.402 -4.969 0.422 -4.969 3.227 c
-4.969 6.249 -2.859 8.073 -0.054 8.073 c
1.048 8.073 1.824 7.842 2.165 7.665 c
1.811 6.331 l
1.375 6.521 0.762 6.685 0.014 6.685 c
-1.852 6.685 -3.199 5.514 -3.199 3.308 c
-3.199 1.28 -2.028 0 0 0 c
-6.127 -1.252 m
-7.801 -1.252 l
-7.801 2.791 l
-11.681 2.791 l
-11.681 -1.252 l
-13.356 -1.252 l
-13.356 7.924 l
-11.681 7.924 l
-11.681 4.248 l
-7.801 4.248 l
-7.801 7.924 l
-6.127 7.924 l
h
-16.174 -1.252 m
-17.005 1.348 l
-19.905 1.348 l
-20.694 -1.252 l
-22.423 -1.252 l
-19.483 7.924 l
-17.345 7.924 l
-14.364 -1.252 l
h
-25.805 -12.253 31.616 31.616 re
-25.805 19.363 m
f
Q
q 1 0 0 1 88.2162 88.5766 cm
0 0 m
-0.054 1.185 -0.123 2.614 -0.109 3.853 c
-0.15 3.853 l
-0.449 2.736 -0.831 1.498 -1.239 0.34 c
-2.587 -3.635 l
-3.866 -3.635 l
-5.092 0.286 l
-5.446 1.457 -5.772 2.709 -6.018 3.853 c
-6.045 3.853 l
-6.086 2.655 -6.14 1.198 -6.208 -0.055 c
-6.413 -3.744 l
-7.978 -3.744 l
-7.365 5.432 l
-5.16 5.432 l
-3.962 1.743 l
-3.635 0.667 -3.349 -0.422 -3.118 -1.443 c
-3.077 -1.443 l
-2.832 -0.449 -2.519 0.681 -2.165 1.756 c
-0.899 5.432 l
1.28 5.432 l
1.811 -3.744 l
0.177 -3.744 l
h
f
Q
q 1 0 0 1 95.8269 88.8489 cm
0 0 m
0.014 0.613 -0.259 1.62 -1.375 1.62 c
-2.41 1.62 -2.846 0.681 -2.914 0 c
h
-2.914 -1.171 m
-2.873 -2.369 -1.947 -2.886 -0.871 -2.886 c
-0.095 -2.886 0.449 -2.764 0.966 -2.587 c
1.211 -3.73 l
0.64 -3.975 -0.15 -4.152 -1.103 -4.152 c
-3.254 -4.152 -4.52 -2.832 -4.52 -0.803 c
-4.52 1.035 -3.404 2.764 -1.28 2.764 c
0.871 2.764 1.579 0.994 1.579 -0.463 c
1.579 -0.776 1.552 -1.021 1.525 -1.171 c
h
f
Q
q 1 0 0 1 103.1923 88.6991 cm
0 0 m
0 0.136 -0.014 0.313 -0.041 0.449 c
-0.191 1.089 -0.721 1.62 -1.484 1.62 c
-2.559 1.62 -3.158 0.667 -3.158 -0.558 c
-3.158 -1.783 -2.559 -2.668 -1.497 -2.668 c
-0.817 -2.668 -0.218 -2.205 -0.054 -1.484 c
-0.014 -1.334 0 -1.171 0 -0.994 c
h
1.675 5.8 m
1.675 -2.001 l
1.675 -2.682 1.702 -3.417 1.729 -3.866 c
0.245 -3.866 l
0.163 -2.818 l
0.136 -2.818 l
-0.259 -3.553 -1.062 -4.016 -2.015 -4.016 c
-3.608 -4.016 -4.86 -2.668 -4.86 -0.626 c
-4.874 1.593 -3.485 2.914 -1.892 2.914 c
-0.98 2.914 -0.327 2.546 -0.027 2.056 c
0 2.056 l
0 5.8 l
h
f
Q
106.664 91.463 1.675 -6.63 re
106.664 84.833 m
108.448 93.314 m
108.448 92.824 108.08 92.416 107.495 92.416 c
106.936 92.416 106.569 92.824 106.569 93.314 c
106.569 93.832 106.95 94.227 107.508 94.227 c
108.08 94.227 108.434 93.832 108.448 93.314 c
f
q 1 0 0 1 113.6622 88.0729 cm
0 0 m
-1.184 0.014 -2.315 -0.231 -2.315 -1.239 c
-2.315 -1.892 -1.892 -2.192 -1.361 -2.192 c
-0.681 -2.192 -0.204 -1.756 -0.041 -1.28 c
0 -1.157 0 -1.035 0 -0.912 c
h
1.634 -1.647 m
1.634 -2.246 1.661 -2.832 1.743 -3.24 c
0.231 -3.24 l
0.109 -2.505 l
0.068 -2.505 l
-0.327 -3.022 -1.021 -3.39 -1.892 -3.39 c
-3.226 -3.39 -3.975 -2.423 -3.975 -1.416 c
-3.975 0.245 -2.492 1.103 -0.041 1.089 c
-0.041 1.198 l
-0.041 1.634 -0.218 2.355 -1.389 2.355 c
-2.042 2.355 -2.723 2.151 -3.172 1.865 c
-3.499 2.954 l
-3.009 3.254 -2.151 3.54 -1.103 3.54 c
1.021 3.54 1.634 2.192 1.634 0.735 c
h
f
Q
Q
BT
/TT0 1 Tf
0 Tc 14 0 0 14 36 733.3608 Tm
(Experts Withdraw Support for Codeine)Tj
( )Tj
0 -1.151 TD
(in Children)Tj
/T1_4 1 Tf
-0.01 Tc 10 0 0 10 36 705.121 Tm
[(Codeine is no longer recommended for use in children.)-9.9 ( )]TJ
0 -1.212 TD
[(After years of debate, the American Academy of Pediatrics)-10 ( )]TJ
0 -1.212 TD
[(\(AAP\) has issued a Clinical Report recommending against)-10 ( )]TJ
0 -1.212 TD
[(the use of codeine for cough or pain in children, regardless)-10 ( )]TJ
0 -1.212 TD
[(of age. The recommendation from the AAP\222)74 (s Section on)-10 ( )]TJ
0 -1.212 TD
[(Anesthesiology and Pain Medicine, Committee on Drugs,)-10 ( )]TJ
0 -1.212 TD
[(notes that codeine is a prodrug of morphine, and the)-9.9 ( )]TJ
T*
[(conversion occurs in the liver)111 (. There is substantial genetic)-10 ( )]TJ
T*
[(variability in the activity of the responsible hepatic enzyme)-10 ( )]TJ
T*
[(leading to signi\037cant individual variation in the effect of)-10 ( )]TJ
T*
[(codeine. Some children experience no effect at all, while)-10 ( )]TJ
T*
[(others are ultrarapid metabolizers, which may result)-10 ( )]TJ
T*
[(in high serum morphine levels. The FDA has received)-10 ( )]TJ
0 -1.212 TD
[(multiple reports of respiratory depression and death)-10 ( )]TJ
0 -1.212 TD
[(after receiving codeine in children, many of whom were)-9.9 ( )]TJ
T*
[(subsequently found to be rapid metabolizers. Children)-10 ( )]TJ
T*
[(with sleep apnea seem to be at particularly high risk. The)-9.9 ( )]TJ
T*
[(FDA and the W)86 (orld Health Organization are considering)-10 ( )]TJ
T*
[(similar warnings. Despite these concerns, codeine continues)-10 ( )]TJ
T*
[(to be commonly prescribed, with more than 800,000)-10 ( )]TJ
T*
[(prescriptions for children < 11 years of age in 2011.)-10 ( )]TJ
T*
[(Unfortunately)92 (, other opioids have similar safety concerns,)-9.9 ( )]TJ
T*
[(precluding their use as an alternative, leaving nonsteroidal)-10 ( )]TJ
0 -1.212 TD
[(anti-in\036ammatory drugs and acetaminophen as options)-9.9 ( )]TJ
0 Tc 0 -1.212 TD
(\()Tj
/T1_5 1 Tf
-0.01 Tc 0.01 Tw 0.323 0 Td
(Pediatrics)Tj
/T1_4 1 Tf
0 Tw ( Sep 2016, e20151648; doi: 10.1542/peds.2016-)Tj
-0.323 -1.212 Td
[(2396\). An FDA advisory panel met last December and by)-10 ( )]TJ
T*
[(an overwhelming majority recommended that the use of)-10 ( )]TJ
T*
[(codeine is contraindicated for the treatment of cough in)-10 ( )]TJ
0.01 Tw T*
(children )Tj
/T1_6 1 Tf
0 Tc 0 Tw 3.689 0 Td
(\036)Tj
/T1_4 1 Tf
-0.01 Tc 0.569 0 Td
[( 18 years of age; however)111 (, the FDA has not yet)-10 ( )]TJ
-4.258 -1.212 Td
(acted on the recommendation.)Tj
/TT0 1 Tf
0 Tc 14 0 0 14 36 325.4044 Tm
[(FD)17.4 (A Actions)]TJ
/T1_4 1 Tf
-0.01 Tc 10 0 0 10 36 313.2846 Tm
[(In a mixed vote, an FDA advisory committee has voted to)-10 ( )]TJ
T*
[(remove the black box warning from varenicline \(Chantix\).)-10 ( )]TJ
T*
(The warning was placed in 2009 after the FDA received re)Tj
0 Tc (-)Tj
-0.01 Tc T*
[(ports of neuropsychiatric events, including depression and)-9.9 ( )]TJ
ET
/CS0 CS 1 SCN
0.5 w
/GS1 gs
q 1 0 0 1 477.3884 698.918 cm
0 0 m
79.62 0 l
S
Q
q 1 0 0 1 306 686.7981 cm
0 0 m
248.318 0 l
S
Q
q 1 0 0 1 306 674.6782 cm
0 0 m
33.64 0 l
S
Q
BT
/GS0 gs
10 0 0 10 306 736.2775 Tm
[(thoughts of suicide. But a company-funded trial published)-10 ( )]TJ
T*
(in April did not show a signi\037cant increase in neuropsychi)Tj
0 Tc (-)Tj
-0.01 Tc T*
(atric adverse events attributable to varenicline or bupropi)Tj
0 Tc (-)Tj
-0.01 Tc T*
(on relative to nicotine patch or placebo \()Tj
/CS0 cs 1 scn
/GS1 gs
0.01 Tw [(http://www)92 (.thelan)]TJ
0 Tc 0 Tw (-)Tj
-0.01 Tc 0.01 Tw T*
(cet.com/journals/lancet/article/PIIS0140-6736\(16\)30272-0/)Tj
0 -1.212 TD
(abstract)Tj
0 0 0 1 k
/GS0 gs
0 Tw [(\). Although some at the FDA criticized the study)-10 ( )]TJ
0 -1.212 TD
[(design, 10 of the 19 committee members voted to remove)-10 ( )]TJ
0 -1.212 TD
[(the warning. Of the dissenters, several voted to amend the)-10 ( )]TJ
0 -1.212 TD
[(current warning, while others voted to keep the current)-10 ( )]TJ
T*
[(warning as is. This is the second time varenicline\222)74 (s manu)]TJ
0 Tc (-)Tj
-0.01 Tc T*
[(facturer has petitioned the FDA to remove the warning,)-9.9 ( )]TJ
T*
(after an unsuccessful attempt in 2014.)Tj
0 -2.424 TD
[(The FDA has approved the \037rst biosimilar to adalimumab)-10 ( )]TJ
0 -1.212 TD
[(\(Humira\). Adalimumab-atto is approved for the same)-10 ( )]TJ
0 -1.212 TD
[(indications as adalimumab, including rheumatoid arthritis,)-10 ( )]TJ
0 -1.212 TD
[(psoriatic arthritis, ankylosing spondylitis, Crohn\222)74 (s disease,)-10 ( )]TJ
0 -1.212 TD
[(ulcerative colitis, plaque psoriasis, and juvenile idiopathic)-10 ( )]TJ
0 -1.212 TD
(arthritis in children )Tj
/T1_6 1 Tf
0 Tc (\037)Tj
/T1_4 1 Tf
-0.01 Tc 8.963 0 Td
[( 4 years of age. The approval was)-10 ( )]TJ
-8.963 -1.212 Td
[(based on structural and functional characterization,)-10 ( )]TJ
T*
[(animal study data, human pharmacokinetic and)-10 ( )]TJ
T*
[(pharmacodynamics data, clinical immunogenicity data,)-10 ( )]TJ
T*
[(and other clinical safety and effectiveness data that)-10 ( )]TJ
T*
[(demonstrate adalimumab-atto is biosimilar to adalimumab.)-10 ( )]TJ
T*
(Adalimumab-atto is marketed as Amjevita.)Tj
0 -2.424 TD
[(The FDA has issued a warning regarding direct-acting)-10 ( )]TJ
0 -1.212 TD
[(antiviral drugs used to treat hepatitis C \(HCV\) and the risk)-9.9 ( )]TJ
0 -1.212 TD
[(of reactivation of hepatitis B \(HBV\) in patients co-infected)-10 ( )]TJ
T*
[(with HBV and HCV)129 (. The FDA has identi\037ed 24 cases of)-10 ( )]TJ
T*
[(HBV reactivation in the last three years, of which two)-10 ( )]TJ
T*
[(patients died and one required a liver transplant. The drugs)-9.9 ( )]TJ
T*
[(implicated include the most commonly used HCV drugs,)-10 ( )]TJ
T*
[(including \(by tradename\) Harvoni, Sovaldi, Daklinza,)-10 ( )]TJ
T*
[(V)37 (iekira Pak, and Zepatier)111 (. The FDA recommends testing)-10 ( )]TJ
T*
[(patients for HBV prior to initiating therapy for HCV)129 (, and)-10 ( )]TJ
0 -1.212 TD
[(monitoring patients for HBV reactivation during and after)-10 ( )]TJ
0 -1.212 TD
[(treatment. The FDA also added a boxed warning to all)-10 ( )]TJ
T*
[(direct-acting antivirals to treat HCV warning about HBV)-10 ( )]TJ
0.01 Tw T*
(reactivation.)Tj
0 Tw 0 -2.424 TD
[(In a controversial decision, the FDA has approved the \037rst)-9.9 ( )]TJ
0 -1.212 TD
(drug to treat the most common childhood form of mus)Tj
0 Tc (-)Tj
-0.01 Tc T*
[(cular dystrophy)92 (. Eteplirsen has been the subject of intense)-10 ( )]TJ
0 -1.212 TD
(lobbying by patient advocacy groups for years, but evi)Tj
0 Tc (-)Tj
-0.01 Tc 0 -1.212 TD
[(dence for effectiveness has been marginal. Approval was)-10 ( )]TJ
0 -1.212 TD
[(based on one study of 12 boys with Duchenne muscular)-9.9 ( )]TJ
0 -1.212 TD
[(dystrophy)92 (, of whom all were treated \(no control group\).)-10 ( )]TJ
0 -1.212 TD
[(The approval also was based on a surrogate endpoint)-10 ( )]TJ
0 -1.212 TD
[(without evidence of improvement in motor function. The)-9.9 ( )]TJ
0 -1.212 TD
[(drug was not recommended for approval by the agency\222)74 (s)-10 ( )]TJ
T*
(expert panel, but the FDA overruled that decision and ap)Tj
0 Tc (-)Tj
-0.01 Tc T*
[(proved the drug on a close vote. The drug also was granted)-10 ( )]TJ
T*
[(fast-track approval and orphan designation, which is used)-10 ( )]TJ
T*
[(to accelerate approval and provide \037nancial incentives to)-10 ( )]TJ
T*
[(companies to develop drugs for rare conditions. Eteplirsen)-10 ( )]TJ
T*
[(is marketed as Exondys 51. Eteplirsen is expected to cost)-10 ( )]TJ
0 -1.212 TD
[(about $300,000 per year)111 (. )]TJ
/CS0 cs 1 scn
/GS1 gs
/C2_0 1 Tf
0 Tc 11.17 0 Td
<0084>Tj
ET
endstream
endobj
24 0 obj
<>>>/Subtype/Form>>stream
0 0 0 1 K
3 w 4 M 0 j 0 J
/GS0 gs
q 1 0 0 1 18 754.5 cm
0 0 m
558 0 l
S
Q
endstream
endobj
10 0 obj
<>
endobj
23 0 obj
<>
endobj
25 0 obj
<>stream
application/postscript
AHCmedia(New)_3 tag options_11.8.13
Travis
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
xmp.did:bdec626a-762d-6946-8d41-56d8de9e49a7
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
xmp.did:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
uuid:5D20892493BFDB11914A8590D31508C8
proof:pdf
converted
from application/pdf to <unknown>
saved
xmp.iid:D27F11740720681191099C3B601C4548
2008-04-17T14:19:15+05:30
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F1174072068118D4ED246B3ADB1C6
2008-05-15T16:23:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FA7F1174072068118D4ED246B3ADB1C6
2008-05-15T17:10:45-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:EF7F117407206811A46CA4519D24356B
2008-05-15T22:53:33-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F07F117407206811A46CA4519D24356B
2008-05-15T23:07:07-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BDDDFD38D0CF24DD
2008-05-16T10:35:43-07:00
Adobe Illustrator CS4
/
converted
from application/pdf to <unknown>
saved
xmp.iid:F97F117407206811BDDDFD38D0CF24DD
2008-05-16T10:40:59-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to <unknown>
saved
xmp.iid:FA7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:26:55-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FB7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:01-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FC7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:29:20-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FD7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:30:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:FE7F117407206811BDDDFD38D0CF24DD
2008-05-16T11:31:22-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B233668C16206811BDDDFD38D0CF24DD
2008-05-16T12:23:46-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B333668C16206811BDDDFD38D0CF24DD
2008-05-16T13:27:54-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:B433668C16206811BDDDFD38D0CF24DD
2008-05-16T13:46:13-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F11740720681197C1BF14D1759E83
2008-05-16T15:47:57-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F87F11740720681197C1BF14D1759E83
2008-05-16T15:51:06-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F11740720681197C1BF14D1759E83
2008-05-16T15:52:22-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FA7F117407206811B628E3BF27C8C41B
2008-05-22T13:28:01-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:FF7F117407206811B628E3BF27C8C41B
2008-05-22T16:23:53-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:07C3BD25102DDD1181B594070CEB88D9
2008-05-28T16:45:26-07:00
Adobe Illustrator CS4
/
converted
from application/vnd.adobe.illustrator to application/vnd.adobe.illustrator
saved
xmp.iid:F87F1174072068119098B097FDA39BEF
2008-06-02T13:25:25-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811BB1DBF8F242B6F84
2008-06-09T14:58:36-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F97F117407206811ACAFB8DA80854E76
2008-06-11T14:31:27-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:0180117407206811834383CD3A8D2303
2008-06-11T22:37:35-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:F77F117407206811818C85DF6A1A75C3
2008-06-27T14:40:42-07:00
Adobe Illustrator CS4
/
saved
xmp.iid:2759AC6B4FA8E211B099CEB363CBA397
2013-04-18T13:43:03-04:00
Adobe Illustrator CS4
/
saved
xmp.iid:5E11DEB5A8216811822A8C4A5BB13D00
2014-01-03T17:39:31-05:00
Adobe Illustrator CS6 (Macintosh)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:13a2ed22-31ef-3e4e-8ae1-9e6a4d59884d
2014-01-06T10:41:10-05:00
Adobe Illustrator CC (Windows)
/
converted
from application/postscript to application/vnd.adobe.illustrator
saved
xmp.iid:bdec626a-762d-6946-8d41-56d8de9e49a7
2014-09-09T14:01:27-04:00
Adobe Illustrator CC 2014 (Windows)
/
Print
False
False
1
3.584901
1.584901
Inches
Black
Default Swatch Group
0
White
CMYK
PROCESS
0.000000
0.000000
0.000000
0.000000
Black
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
CMYK Red
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
CMYK Yellow
CMYK
PROCESS
0.000000
0.000000
100.000000
0.000000
CMYK Green
CMYK
PROCESS
100.000000
0.000000
100.000000
0.000000
CMYK Cyan
CMYK
PROCESS
100.000000
0.000000
0.000000
0.000000
CMYK Blue
CMYK
PROCESS
100.000000
100.000000
0.000000
0.000000
CMYK Magenta
CMYK
PROCESS
0.000000
100.000000
0.000000
0.000000
C=15 M=100 Y=90 K=10
CMYK
PROCESS
15.000000
100.000000
90.000000
10.000000
C=0 M=90 Y=85 K=0
CMYK
PROCESS
0.000000
90.000000
85.000000
0.000000
C=0 M=80 Y=95 K=0
CMYK
PROCESS
0.000000
80.000000
95.000000
0.000000
C=0 M=50 Y=100 K=0
CMYK
PROCESS
0.000000
50.000000
100.000000
0.000000
C=0 M=35 Y=85 K=0
CMYK
PROCESS
0.000000
35.000000
85.000000
0.000000
C=5 M=0 Y=90 K=0
CMYK
PROCESS
5.000000
0.000000
90.000000
0.000000
C=20 M=0 Y=100 K=0
CMYK
PROCESS
20.000000
0.000000
100.000000
0.000000
C=50 M=0 Y=100 K=0
CMYK
PROCESS
50.000000
0.000000
100.000000
0.000000
C=75 M=0 Y=100 K=0
CMYK
PROCESS
75.000000
0.000000
100.000000
0.000000
C=85 M=10 Y=100 K=10
CMYK
PROCESS
85.000000
10.000000
100.000000
10.000000
C=90 M=30 Y=95 K=30
CMYK
PROCESS
90.000000
30.000000
95.000000
30.000000
C=75 M=0 Y=75 K=0
CMYK
PROCESS
75.000000
0.000000
75.000000
0.000000
C=80 M=10 Y=45 K=0
CMYK
PROCESS
80.000000
10.000000
45.000000
0.000000
C=70 M=15 Y=0 K=0
CMYK
PROCESS
70.000000
15.000000
0.000000
0.000000
C=85 M=50 Y=0 K=0
CMYK
PROCESS
85.000000
50.000000
0.000000
0.000000
C=100 M=95 Y=5 K=0
CMYK
PROCESS
100.000000
95.000000
5.000000
0.000000
C=100 M=100 Y=25 K=25
CMYK
PROCESS
100.000000
100.000000
25.000000
25.000000
C=75 M=100 Y=0 K=0
CMYK
PROCESS
75.000000
100.000000
0.000000
0.000000
C=50 M=100 Y=0 K=0
CMYK
PROCESS
50.000000
100.000000
0.000000
0.000000
C=35 M=100 Y=35 K=10
CMYK
PROCESS
35.000000
100.000000
35.000000
10.000000
C=10 M=100 Y=50 K=0
CMYK
PROCESS
10.000000
100.000000
50.000000
0.000000
C=0 M=95 Y=20 K=0
CMYK
PROCESS
0.000000
95.000000
20.000000
0.000000
C=25 M=25 Y=40 K=0
CMYK
PROCESS
25.000000
25.000000
40.000000
0.000000
C=40 M=45 Y=50 K=5
CMYK
PROCESS
40.000000
45.000000
50.000000
5.000000
C=50 M=50 Y=60 K=25
CMYK
PROCESS
50.000000
50.000000
60.000000
25.000000
C=55 M=60 Y=65 K=40
CMYK
PROCESS
55.000000
60.000000
65.000000
40.000000
C=25 M=40 Y=65 K=0
CMYK
PROCESS
25.000000
40.000000
65.000000
0.000000
C=30 M=50 Y=75 K=10
CMYK
PROCESS
30.000000
50.000000
75.000000
10.000000
C=35 M=60 Y=80 K=25
CMYK
PROCESS
35.000000
60.000000
80.000000
25.000000
C=40 M=65 Y=90 K=35
CMYK
PROCESS
40.000000
65.000000
90.000000
35.000000
C=40 M=70 Y=100 K=50
CMYK
PROCESS
40.000000
70.000000
100.000000
50.000000
C=50 M=70 Y=80 K=70
CMYK
PROCESS
50.000000
70.000000
80.000000
70.000000
PANTONE 288 U
SPOT
100.000000
CMYK
100.000000
67.000002
0.000000
23.000000
PANTONE 313 C
SPOT
100.000000
CMYK
100.000000
0.000000
8.000200
13.000500
PANTONE 313 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.000000
13.000000
PANTONE 187 U
SPOT
100.000000
CMYK
0.000000
100.000000
78.999299
19.999699
PANTONE 309 U
SPOT
100.000000
CMYK
100.000000
0.000000
8.999600
72.000098
Grays
1
C=0 M=0 Y=0 K=100
CMYK
PROCESS
0.000000
0.000000
0.000000
100.000000
C=0 M=0 Y=0 K=90
CMYK
PROCESS
0.000000
0.000000
0.000000
89.999400
C=0 M=0 Y=0 K=80
CMYK
PROCESS
0.000000
0.000000
0.000000
79.998800
C=0 M=0 Y=0 K=70
CMYK
PROCESS
0.000000
0.000000
0.000000
69.999700
C=0 M=0 Y=0 K=60
CMYK
PROCESS
0.000000
0.000000
0.000000
59.999100
C=0 M=0 Y=0 K=50
CMYK
PROCESS
0.000000
0.000000
0.000000
50.000000
C=0 M=0 Y=0 K=40
CMYK
PROCESS
0.000000
0.000000
0.000000
39.999400
C=0 M=0 Y=0 K=30
CMYK
PROCESS
0.000000
0.000000
0.000000
29.998800
C=0 M=0 Y=0 K=20
CMYK
PROCESS
0.000000
0.000000
0.000000
19.999700
C=0 M=0 Y=0 K=10
CMYK
PROCESS
0.000000
0.000000
0.000000
9.999100
C=0 M=0 Y=0 K=5
CMYK
PROCESS
0.000000
0.000000
0.000000
4.998800
Brights
1
C=0 M=100 Y=100 K=0
CMYK
PROCESS
0.000000
100.000000
100.000000
0.000000
C=0 M=75 Y=100 K=0
CMYK
PROCESS
0.000000
75.000000
100.000000
0.000000
C=0 M=10 Y=95 K=0
CMYK
PROCESS
0.000000
10.000000
95.000000
0.000000
C=85 M=10 Y=100 K=0
CMYK
PROCESS
85.000000
10.000000
100.000000
0.000000
C=100 M=90 Y=0 K=0
CMYK
PROCESS
100.000000
90.000000
0.000000
0.000000
C=60 M=90 Y=0 K=0
CMYK
PROCESS
60.000000
90.000000
0.003100
0.003100
Adobe PDF library 10.01
endstream
endobj
18 0 obj
<>
endobj
19 0 obj
<>
endobj
20 0 obj
<>
endobj
21 0 obj
<>
endobj
22 0 obj
<>
endobj
11 0 obj
<>
endobj
13 0 obj
<>
endobj
12 0 obj
<>
endobj
14 0 obj
<>
endobj
44 0 obj
<>
endobj
45 0 obj
<>stream
HdNV{q)>J\> i\?m 6eȷ<O/fst]~x{_Nϯ7ww˛oxx2r/?2އp?D??yz{qfzOt:m-_7͆